RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Royalty Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Market Cap | $34.66B | $197.05M |
| Enterprise Value | $45.73B | $106.56M |
| PE Ratio | 34.24 | 20.52 |
| PS Ratio | 13.67 | 3.93 |
| P/OCF Ratio | 11.64 | 13.78 |
Enterprise value
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| EV / Sales | 18.03 | 2.69 |
| EV / EBITDA | 30.25 | 14.86 |
| EV / EBIT | 30.25 | 19.00 |
Income (trailing twelve months)
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Revenue | $2.54B | $57.94M |
| Operating Income | $1.51B | -$21.44M |
| Pretax Income | $1.35B | -$14.45M |
| Net Income | $815.00M | -$22.46M |
| EBITDA | $1.51B | -$16.91M |
| EPS (Diluted) | $1.76 | -$0.83 |
Margins
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Operating Margin | 59.6% | -44.5% |
| Pretax Margin | 53.2% | -13.0% |
| Profit Margin | 32.1% | -39.2% |
| EBITDA Margin | 59.6% | -31.3% |
Returns
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | 4.27% | -41.0% |
| Return on Capital Employed (ROCE) | 7.88% | -37.8% |
Growth
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 10.0% | 6.01% |
| Net Income Growth (YoY) | -20.4% | -37.7% |
| EPS Growth (YoY) | -19.3% | -29.2% |
| Revenue Growth (3Y CAGR) | 2.06% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.30% | 6.42% |
| EPS Growth (3Y CAGR) | 161.1% | -0.17% |
| EPS Growth (5Y CAGR) | 6.16% | 3.77% |
Balance sheet
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $836.99M | $62.42M |
| Total Debt | $8.96B | $120.13M |
| Net Cash (Debt) | -$8.12B | $15.68M |
| Net Cash Per Share | -$14.13 | $0.65 |
| Working Capital | $1.13B | $75.77M |
Financial position
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Current Ratio | 2.80 | 3.30 |
| Quick Ratio | 1.33 | 2.39 |
| Debt / EBITDA | 5.93 | 3.35 |
| Net Debt / EBITDA | 5.37 | 2.22 |
| Interest Coverage | 4.19 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | $2.98B | -$12.35M |
Efficiency
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Revenue Per Employee | $25.36M | $398.96K |
| Profits Per Employee | $8.15M | -$732.08K |
| Employee Count | 100 | 73 |
Dividends and yields
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Earnings Yield | 2.35% | -21.2% |
| Buyback Yield | 0.93% | -0.58% |
| Shareholder Yield | 0.93% | 0.00% |
Shares
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 575,001,000 | 59,128,900 |
| Shares Change (YoY) | -3.94% | 11.1% |
| Float | 445,207,000 | 48,744,500 |
| Shares Held by Insiders | 22.6% | 11.8% |
| Shares Held by Institutions | 63.8% | 59.4% |
Taxes
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
| Effective Tax Rate | 0.00% | 20.6% |
Scores
| Measure | Royalty Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 2.69 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Royalty Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.